BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells.

Zahra Fathi(National Cancer Institute), Martha H. Corjay(National Cancer Institute), Hagit Shapira(National Cancer Institute), Etsuko Wada(National Cancer Institute), Richard V. Benya(National Cancer Institute), Robert T. Jensen(National Cancer Institute), Jean Viallet(National Cancer Institute), E. A. Sausville(National Cancer Institute), James F. Battey(National Cancer Institute)
Journal of Biological Chemistry
March 1, 1993
Cited by 299Open Access
Full Text

Abstract

The bombesin (BN)-like peptides mediate a diverse spectrum of biological activities and have been implicated as autocrine growth factors in the pathogenesis and progression of some human small cell lung carcinoma tumors. Previously, two mammalian BN-like peptide receptor subtypes, gastrin-releasing peptide receptor and neuromedin-B receptor, have been cloned and characterized. In this study, we have isolated and characterized human genomic and complementary DNA (cDNA) clones encoding a new BN-like peptide receptor subtype, BN receptor subtype 3 (BRS-3). Expression of BRS-3 cDNA in Xenopus oocytes encodes a functional receptor that is specifically activated by BN-like peptides. Chromosome mapping studies indicate that the BRS-3 gene is located on human chromosome X. BRS-3 mRNA expression in rat tissues is limited to secondary spermatocytes in testis. In contrast, BRS-3 mRNA is widely expressed in a panel of human cell lines from all histological types of lung carcinoma. These results suggest a role for BN-like peptides and their receptors in mammalian reproductive physiology and also indicate that BRS-3 could serve as a potential therapeutic target for human lung carcinoma.


Related Papers

No related papers found

Powered by citation graph analysis